These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2342972)

  • 21. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intraarterial high-dose adriamycin for patients with skeletal or soft tissue sarcoma].
    Yoh S; Takagishi N; Iwasaki H; Eimoto T; Ono Y; Okasaki M
    Gan No Rinsho; 1983 Aug; 29(10):1263-73. PubMed ID: 6632206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
    Boccia R; Anné PR; Bourhis J; Brizel D; Daly C; Holloway N; Hymes S; Koukourakis M; Kozloff M; Turner M; Wasserman T
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):302-9. PubMed ID: 15337569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K
    Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinorelbine and venous irritation: optimal parenteral administration.
    de Lemos ML
    J Oncol Pharm Pract; 2005 Jun; 11(2):79-81. PubMed ID: 16460608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High incidence of local venous reactions to esorubicin.
    Lee KM; Dorr RT; Robertone A
    Invest New Drugs; 1987; 5(1):31-5. PubMed ID: 3597000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adriamycin (doxorubicin)].
    Ogura M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1331-8. PubMed ID: 11681238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles.
    Baptista RJ; Driscoll DF; Gallagher JA; O'Keefe E; Dumas GJ; Hammer SM; Pacella PP
    Clin Pharm; 1987 Apr; 6(4):314-8. PubMed ID: 3665384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study.
    Uslusoy E; Mete S
    J Am Acad Nurse Pract; 2008 Apr; 20(4):172-80. PubMed ID: 18387013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urticaria following intravenous doxorubicin administration.
    Souhami L; Feld R
    JAMA; 1978 Oct; 240(15):1624-6. PubMed ID: 691151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amiodarone-induced phlebitis remains an issue in spite of measures to reduce its occurrence.
    Dixon HA; Hort AL; Wright CM
    J Vasc Access; 2019 Nov; 20(6):786-787. PubMed ID: 30958088
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical efficacy and safety of two concentrations of intravenous nicardipine hydrochloride for nicardipine-related phlebitis in patients with preeclampsia.
    Ye F; Lu Q; Kong B; Li Y
    Can J Physiol Pharmacol; 2022 Apr; 100(4):291-294. PubMed ID: 35213242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extravasation of doxorubicin from vascular access devices.
    Curran CF; Luce JK
    Sel Cancer Ther; 1990; 6(2):103-7. PubMed ID: 2367752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reaction to doxorubicin.
    Collins JA
    Drug Intell Clin Pharm; 1984 May; 18(5):402-3. PubMed ID: 6233126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An unusual allergic reaction in a vein following intravenous adriamycin.
    Ostrowski MJ
    Clin Oncol; 1976 Jun; 2(2):179-80. PubMed ID: 954260
    [No Abstract]   [Full Text] [Related]  

  • 38. Ocular adverse reactions associated with adriamycin (doxorubicin).
    Curran CF; Luce JK
    Am J Ophthalmol; 1989 Dec; 108(6):709-11. PubMed ID: 2596552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin-associated facial flushing.
    Curran CF
    Arch Dermatol; 1992 Oct; 128(10):1408. PubMed ID: 1417039
    [No Abstract]   [Full Text] [Related]  

  • 40. "Getting Under Your Skin": First Reported Case of Transient Reactive Phlebitis Involving Vancomycin Infusion Therapy.
    Azimi-Ghomi O; Napier A
    Cureus; 2021 Oct; 13(10):e18471. PubMed ID: 34754636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.